The LWP is devoted to advancing research and promoting education on the role of stem cell transplantation in the management of patients with lymphoid malignancies. The management of patients with lymphoma has changed extraordinarily in the last 10-15 years. The advent of rituximab has resulted in a significant improvement in the outcome of several types of lymphoma. More recently, a plethora of new agents with a very strong biological rational is becoming available for the treatment of patients with lymphoid malignancies. In parallel, advances in hematopoietic cell transplantation technology, such as reduced toxicity conditioning, haplo-transplantation, and CAR T cell therapy have improved the outcome and widened the applicability of stem cell transplantation in lymphoma, particularly for elderly patients and those without a matched donor.
The challenge is to continuously define the appropriate place for stem cell transplant in the therapeutic algorithm of patients with lymphoma in concert with the novel pharmacological options. With the largest database of patients that have undergone a stem cell transplant for lymphoma combined with the expertise of the transplant community, the LWP is in a privileged position to contribute to this aim.
Educational courses and Meetings
EBMT Annual Meeting in Marseille
Click HERE to view the activities of the Lymphoma Working Party
List of Members
The LWP is composed of a panel of experts on Hodgkin lymphoma and non Hodgkin lymphoma, including diffuse large B-cell lymphoma, T-cell lymphomas, mantle cell lymphoma, follicular lymphoma and Waldenström macroglobulinemia. The panel is supported by the excellent help of Hervé Finel, Study Coordinator, and Ariane Boumendil, Statistician.
||University of Heidelberg|
||University Of Heidelberg|
||St Bartholomew’s Hospital|
||University Hospital Bristol|
||Asklepios Klinik St. Georg|
||Maastricht University Hospital|
||Catalan Institute of Oncology|
Checkpoint inhibition for treating Hodgkin and Non-Hodgkin lymphoma in the context of allogeneic stem cell transplantation: A survey-based registry study of the EBMT Lymphoma Working Party.
This study aims to investigate safety and efficacy of immune checkpoint inhibitor treatment before and after allogeneic stem cell transplantation in NHL and HL.
Main objectives of the study are to investigate if:
- checkpoint blockade pre-treatment might influence the outcome of a subsequent allo-HSCT
- post-transplant checkpoint blockade for treatment of lymphoma relapse is safe and effective
- Patients who received an allo-HSCT after January 2014
- Documented pre or post-transplant exposure to Immune checkpoint inhibitors
- Diagnosis of NHL or HL
- Age over 18 years at transplant
- Donor: SIB, UD, haplo-identical donor, cord blood donor
- Any conditioning regimen
To fill in the survey please click HERE
The joint effort of the team has resulted in a very active portfolio of ongoing studies and numerous presentations in international meetings and publications in peer-reviewed journals. This includes both retrospective and prospective studies, as well as guidelines and position papers.
Examples of recent publications
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Robinson S et al; European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Leukemia. 2015
Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Montoto S et al; Haematologica. 2013
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. Pettengell R et al; J Clin Oncol. 2013
Click HERE to view the publication list
Studies coordinated by the LWP
- 2009-N-02 Stem cell transplantation in blastic plasmocytoid dendritic cell neoplasia. A Joint NIS with the ALWP
- 2013-N-02 Survey/NIS BTK/BCL2 inhibitors prior to HSCT
- 2015-R-03 Relapse after autoSCT for DLBCL
- 2015-R-01H BV as bridge to transplant in HL
- 2015-R-FL Relapse post autoSCT in FL
- 2015-R-08 HaploSCT in DLBCL (with CIBMTR)
- 2016-R-01 PWI survey post allo (with CMWP)
- 1998-P-01 Lym1-long follow up
Click HERE to view the Current Research list
Click HERE to submit a proposal to the LWP for a new study
How to get involved?
Please contact the Chairperson or the Secretary.
Follow us on Twitter @LymphomaWP_EBMT